Base de dados : MEDLINE
Pesquisa : I01.880.604.583.458.650 [Categoria DeCS]
Referências encontradas : 8847 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 885 ir para página                         

  1 / 8847 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29361660
[Au] Autor:Steiner DJ; Thomson Reuters Accelus.
[Ti] Título:Pharmaceuticals and Medical Devices: Business Practices.
[So] Source:Issue Brief Health Policy Track Serv;2017:1-38, 2017 Dec 26.
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Indústria Farmacêutica/organização & administração
Farmacoeconomia
Legislação de Medicamentos
Medicamentos sob Prescrição/economia
[Mh] Termos MeSH secundário: Analgésicos Opioides
Leis Antitruste
Suplementos Nutricionais
Custos de Medicamentos
Controle de Medicamentos e Entorpecentes/legislação & jurisprudência
Medicamentos Genéricos
Epinefrina/economia
Epinefrina/uso terapêutico
Fraude
Seres Humanos
Prescrição Inadequada
Marketing de Serviços de Saúde
Medicaid
Medicare
Uso Off-Label
Patentes como Assunto
Desvio de Medicamentos sob Prescrição
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics, Opioid); 0 (Drugs, Generic); 0 (Prescription Drugs); YKH834O4BH (Epinephrine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180219
[Lr] Data última revisão:
180219
[Sb] Subgrupo de revista:T
[Da] Data de entrada para processamento:180124
[St] Status:MEDLINE


  2 / 8847 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29366356
[Au] Autor:Godar M; de Haard H; Blanchetot C; Rasser J
[Ad] Endereço:a argenx BVBA , Zwijnaarde , Belgium.
[Ti] Título:Therapeutic bispecific antibody formats: a patent applications review (1994-2017).
[So] Source:Expert Opin Ther Pat;28(3):251-276, 2018 Mar.
[Is] ISSN:1744-7674
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Bispecific antibodies have become increasingly of interest by enabling new therapeutic applications such as retargeting cellular immunity towards tumor cells. About 23 bispecific antibody platforms have therefore been developed, generating about 62 molecules which are currently being evaluated for potential treatment of a variety of indications, such as cancer and inflammatory diseases, among which three molecules were approved. This class of drugs will represent a multi-million-dollar market over the coming years. Many companies have consequently invested in the development of bispecific antibody platforms, creating an important patent activity in this field. Areas covered: The present review gives an overview of the patent literature over the period 1994-2017 of different immunoglobulin gamma-based bispecific antibody platforms and the molecules approved or in clinical trials. Expert opinion: Bispecific antibodies are progressively accepted as potentially superior therapeutic molecules in a broad range of diseases. This frantic activity creates a maze of hundreds of patents that pose considerable legal risks for both newcomers and established companies. It can consecutively be anticipated that the number of patent conflicts will increase. Nevertheless, it can be expected that patents related to the use of a bispecific antibody will have tremendous commercial value.
[Mh] Termos MeSH primário: Anticorpos Biespecíficos/administração & dosagem
Desenho de Drogas
Imunoglobulina G/imunologia
[Mh] Termos MeSH secundário: Anticorpos Biespecíficos/imunologia
Antineoplásicos/administração & dosagem
Antineoplásicos/imunologia
Indústria Farmacêutica
Seres Humanos
Imunidade Celular/imunologia
Neoplasias/tratamento farmacológico
Neoplasias/imunologia
Patentes como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibodies, Bispecific); 0 (Antineoplastic Agents); 0 (Immunoglobulin G)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180126
[St] Status:MEDLINE
[do] DOI:10.1080/13543776.2018.1428307


  3 / 8847 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29338548
[Au] Autor:Cioffi CL
[Ad] Endereço:a Departments of Basic and Clinical Sciences and Pharmaceutical Sciences , Albany College of Pharmacy and Health Sciences , Albany , NY , USA.
[Ti] Título:Glycine transporter-1 inhibitors: a patent review (2011-2016).
[So] Source:Expert Opin Ther Pat;28(3):197-210, 2018 Mar.
[Is] ISSN:1744-7674
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Numerous research groups have developed GlyT-1 inhibitors in the pursuit of providing a novel antipsychotic treatment for schizophrenia. Despite multiple compounds advancing into clinical trials, a GlyT-1 inhibitor has yet to emerge to treat patients. However, the approach remains heavily investigated as it presents potential therapeutic utility for several other CNS and non-CNS-related indications. Areas covered: This review discusses various GlyT-1 inhibitor chemotypes identified and provides an overview of patent applications filed and published during the period of 2011-2016. The review largely focuses on composition of matter patent applications, although two recently disclosed method of use patents are discussed. Clinical reports are also disseminated. Expert opinion: Mounting clinical failures with schizophrenic patients have blunted enthusiasm for GlyT-1 inhibition as an approach to treat the disease. However, research in the area remains quite active, as therapeutic potential for several additional indications has emerged. There are numerous and diverse GlyT-1 chemotypes now available that exhibit differentiating modes of binding and ligand-target binding kinetics, and this rich diversity of chemical matter may help further elucidate the target's pharmacological role in various indications and lead to the identification of a compound with optimal properties that may someday become a drug.
[Mh] Termos MeSH primário: Antipsicóticos/farmacologia
Desenho de Drogas
Proteínas da Membrana Plasmática de Transporte de Glicina/antagonistas & inibidores
[Mh] Termos MeSH secundário: Animais
Seres Humanos
Patentes como Assunto
Esquizofrenia/tratamento farmacológico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antipsychotic Agents); 0 (Glycine Plasma Membrane Transport Proteins); 0 (SLC6A9 protein, human)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180118
[St] Status:MEDLINE
[do] DOI:10.1080/13543776.2018.1429408


  4 / 8847 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29334795
[Au] Autor:Lazewska D; Kiec-Kononowicz K
[Ad] Endereço:a Department of Technology and Biotechnology of Drugs , Jagiellonian University Medical College , Kraków , Poland.
[Ti] Título:Progress in the development of histamine H receptor antagonists/inverse agonists: a patent review (2013-2017).
[So] Source:Expert Opin Ther Pat;28(3):175-196, 2018 Mar.
[Is] ISSN:1744-7674
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Since years, ligands blocking histamine H receptor (H R) activity (antagonists/inverse agonists) are interesting targets in the search for new cures for CNS disorders. Intensive works done by academic and pharmaceutical company researchers have led to many potent and selective H R antagonists/inverse agonists. Some of them have reached to clinical trials. Areas covered: Patent applications from January 2013 to September 2017 and the most important topics connected with H R field are analysed. Espacenet, Patentscope, Pubmed, GoogleScholar or Cochrane Library online databases were principially used to collect all the materials. Expert opinion: The research interest in histamine H R field is still high although the number of patent applications has decreased during the past 4 years (around 20 publications). Complexity of histamine H R biology e.g. many isoforms, constitutive activity, heteromerization with other receptors (dopamine D , D , adenosine A ) and pharmacology make not easy realization and evaluation of therapeutic potential of anti-H R ligands. First results from clinical trials have verified potential utility of histamine H R antagonist/inverse agonists in some diseases. However, more studies are necessary for better understanding of an involvement of the histaminergic system in CNS-related disorders and helping more ligands approach to clinical trials and the market. Lists of abbreviations: hAChEI - human acetylcholinesterase inhibitor; hBuChEI - human butyrylcholinesterase inhibitor; hMAO - human monoamine oxidase; MAO - monoamine oxidase.
[Mh] Termos MeSH primário: Desenho de Drogas
Agonismo Inverso de Drogas
Antagonistas dos Receptores Histamínicos H3/farmacologia
[Mh] Termos MeSH secundário: Animais
Doenças do Sistema Nervoso Central/tratamento farmacológico
Doenças do Sistema Nervoso Central/fisiopatologia
Seres Humanos
Ligantes
Patentes como Assunto
Receptores Histamínicos H3/efeitos dos fármacos
Receptores Histamínicos H3/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Histamine H3 Antagonists); 0 (Ligands); 0 (Receptors, Histamine H3)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180117
[St] Status:MEDLINE
[do] DOI:10.1080/13543776.2018.1424135


  5 / 8847 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29324067
[Au] Autor:Carradori S; Secci D; Petzer JP
[Ad] Endereço:a Department of Pharmacy , "G. d'Annunzio" University of Chieti-Pescara , Chieti , Italy.
[Ti] Título:MAO inhibitors and their wider applications: a patent review.
[So] Source:Expert Opin Ther Pat;28(3):211-226, 2018 Mar.
[Is] ISSN:1744-7674
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Monoamine oxidase (MAO) inhibitors, after the initial 'golden age', are currently used as third-line antidepressants (selective MAO-A inhibitors) or clinically enrolled as co-adjuvants for neurodegenerative diseases (selective MAO-B inhibitors). However, the research within this field is always increasing due to their pivotal role in modulating synaptic functions and monoamines metabolism. Areas covered: In this paper, MAO inhibitors (2015-2017) are disclosed ordering all the patents according to their chemical scaffold. Structure-activity relationships (SARs) are extrapolated for the most investigated chemotypes (coumarins, pyrazole/oxazepinones, (hetero)arylamides). 108 Compounds are divided into two main groups: newly synthesized molecules and naturally-occurring metabolites. Finally, new therapeutic options are outlined to ensure a more complete view on the potential of these inhibitors. Expert opinion: New proposed MAO inhibitors are endowed with a marked isoform selectivity, with innovative therapeutic potential toward other targets (gliomas, inflammation, muscle dystrophies, migraine, chronic pain, pseudobulbar affect), and with a promising ability to address multi-faceted pathologies such as Alzheimer's disease. The increasing number of patents is analyzed collecting data from 2002 to 2017.
[Mh] Termos MeSH primário: Desenho de Drogas
Inibidores da Monoaminoxidase/farmacologia
Doenças Neurodegenerativas/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Antidepressivos/química
Antidepressivos/farmacologia
Seres Humanos
Monoaminoxidase/efeitos dos fármacos
Monoaminoxidase/metabolismo
Inibidores da Monoaminoxidase/química
Doenças Neurodegenerativas/fisiopatologia
Patentes como Assunto
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antidepressive Agents); 0 (Monoamine Oxidase Inhibitors); EC 1.4.3.4 (Monoamine Oxidase)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180112
[St] Status:MEDLINE
[do] DOI:10.1080/13543776.2018.1427735


  6 / 8847 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29298119
[Au] Autor:Kiran S; Kulkarni M
[Ad] Endereço:a Council of Scientific and Industrial Research-Unit for Research and Development of Information Products (CSIR-URDIP) , India.
[Ti] Título:Secondary patents in the pharmaceutical industry: missing the wood for the trees?
[So] Source:Expert Opin Ther Pat;28(3):241-250, 2018 Mar.
[Is] ISSN:1744-7674
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The critics of the Innovator pharmaceutical industry allege that secondary patents are trivial modifications over the primary patent, which extend its term and delay the entry of the generics in the market place. The protagonists regard secondary patents a result of continuous research and development (R&D), which help them introduce and protect new, differentiated products. Areas covered: The areas covered are Product life cycle management (PLCM), Drug approval process, Orange book (OB) listed patents, US patent data. Expert opinion: Our analysis of the patents and products of four innovators viz., AstraZeneca, Takeda, Eisai and Wyeth in the field of proton pump inhibitors (PPI's) and Merck and Pfizer in the field of Statins shows that secondary patents help innovators sustain competition against other innovators in the specific product segment. The number of secondary patents listed in OB per NCE depends on the innovators interest in exploiting the NCE, the success of R & D effort and product lifecycle management strategy in the wake of market competition. Market entry decisions of innovators are strategic rather than a mere fallout of the secondary patents granted. Entry of another innovator is more unpredictable and hurts the first entrant more vis a vis the entry of generics who can enter the market when the patents protecting a product are no more enforceable, and hence more predictable. Generic entry in the field of PPI's shows that the term of the primary patent is not extended by the secondary patents.
[Mh] Termos MeSH primário: Aprovação de Drogas/legislação & jurisprudência
Desenho de Drogas
Indústria Farmacêutica/legislação & jurisprudência
[Mh] Termos MeSH secundário: Aprovação de Drogas/economia
Indústria Farmacêutica/economia
Medicamentos Genéricos/economia
Competição Econômica/legislação & jurisprudência
Seres Humanos
Patentes como Assunto
Pesquisa/economia
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Drugs, Generic)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180104
[St] Status:MEDLINE
[do] DOI:10.1080/13543776.2018.1424134


  7 / 8847 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29297703
[Au] Autor:Kabir KMM; Donald WA
[Ad] Endereço:a School of Chemistry , University of New South Wales, NSW , Sydney , Australia.
[Ti] Título:Cancer breath testing: a patent review.
[So] Source:Expert Opin Ther Pat;28(3):227-239, 2018 Mar.
[Is] ISSN:1744-7674
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Human breath can contain thousands of volatile organic compounds (VOCs) and semi-volatile compounds that are related to metabolism and other biochemical processes. The presence of cancer cells can affect the identity and abundances of chemicals in breath when compared to those in healthy control subjects, which can be used to indicate the likelihood of a patient having cancer. Recently, the chemical analysis of exhaled breath from patients has been shown to be promising for diagnosing many different types of cancers, including lung, breast, colon, head, neck, and prostate, along with pre-cancerous conditions (dysplasia). Areas covered: Here, we reviewed the sampling, analytical and data analysis methods reported in the recent patent literature related to cancer breath testing (2014-2017). In addition, the different types of cancer biomarkers that were disclosed are discussed. Expert opinion: The major advantages of breath testing compared to conventional X-ray and imaging based methods includes simplicity of use, non-invasiveness, and the potential to detect cancer at a relatively early stage. Such methods are also suitable to perform population screening because of their non-invasiveness. However, the establishment of standard sampling, detection and quantification methods for breath testing is required before the methods can be employed for clinical diagnosis.
[Mh] Termos MeSH primário: Testes Respiratórios/métodos
Neoplasias/diagnóstico
Compostos Orgânicos Voláteis/análise
[Mh] Termos MeSH secundário: Biomarcadores Tumorais/análise
Testes Respiratórios/instrumentação
Detecção Precoce de Câncer
Seres Humanos
Estadiamento de Neoplasias
Neoplasias/patologia
Patentes como Assunto
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Volatile Organic Compounds)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180104
[St] Status:MEDLINE
[do] DOI:10.1080/13543776.2018.1423680


  8 / 8847 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29224409
[Au] Autor:Glorikian H; Warburg RJ; Moore K; Malinowski J
[Ad] Endereço:a New Ventures , VA , USA.
[Ti] Título:Intellectual property considerations for molecular diagnostic development with emphasis on companion diagnostics.
[So] Source:Expert Opin Ther Pat;28(2):123-128, 2018 Feb.
[Is] ISSN:1744-7674
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The development of molecular diagnostics is a complex endeavor, with multiple regulatory pathways to consider and numerous approaches to development and commercialization. Companion diagnostics, devices which are "essential for the safe and effective use of a corresponding drug or diagnostic product" (see U.S. Food & Drug Administration, In Vitro Diagnostics - Companion Diagnostics, U.S. Dept. of Health & Human Services(2016), available at https://www.fda.gov/medicaldevices/productsandmedicalprocedures/invitrodiagnostics/ucm407297.htm ) and complementary diagnostics, which are more broadly associated with a class of drug, are becoming increasingly important as integral components of the implementation of precision medicine. Areas covered: The following article will highlight the intellectual property ('IP') considerations pertinent to molecular diagnostics development with special emphasis on companion diagnostics. Expert opinion/commentary Summary: For all molecular diagnostics, intellectual property (IP) concerns are of paramount concern, whether the device will be marketed only in the United States or abroad. Taking steps to protect IP at each stage of product development is critical to optimize profitability of a diagnostic product. Also the legal framework around IP protection of diagnostic technologies has been changing over the previous few years and can be expected to continue to change in the foreseeable near future, thus, a comprehensive IP strategy should take into account the fact that changes in the law can be expected.
[Mh] Termos MeSH primário: Propriedade Intelectual
Técnicas de Diagnóstico Molecular
Patologia Molecular/legislação & jurisprudência
[Mh] Termos MeSH secundário: Seres Humanos
Patentes como Assunto
Medicina de Precisão/métodos
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171212
[St] Status:MEDLINE
[do] DOI:10.1080/13543776.2018.1409209


  9 / 8847 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29210300
[Au] Autor:Lv PC; Jiang AQ; Zhang WM; Zhu HL
[Ad] Endereço:a State Key Laboratory of Pharmaceutical Biotechnology , Nanjing University , Nanjing P. R. China.
[Ti] Título:FAK inhibitors in Cancer, a patent review.
[So] Source:Expert Opin Ther Pat;28(2):139-145, 2018 Feb.
[Is] ISSN:1744-7674
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that localizes at sites of cell adhesion to the extracellular matrix (ECM) and mediates signalling events downstream of integrin engagement of the ECM. FAK is known to regulate cell survival, proliferation and migration. Areas covered: FAK expression has also been shown to be up-regulated in many cancer types. Previous study also indicates that FAK-mediated signaling and functions are intrinsically involved in the progression of tumor aggressiveness, suggesting that FAK is a promising target for anticancer therapies. Small molecule FAK inhibitors have been developed and are being tested in clinical phase trials. Expert Opinion: These inhibitors have demonstrated to be effective by inducing tumor cell apoptosis in addition to reducing metastasis and angiogenesis. In this review, we give updates on the design, synthesis and structure-activity relationship analysis of small molecule FAK inhibitors discovered from 2015 until now. We also review the FAK inhibitors that are in clinical development and highlight the future prospects.
[Mh] Termos MeSH primário: Proteína-Tirosina Quinases de Adesão Focal/antagonistas & inibidores
Neoplasias/tratamento farmacológico
Inibidores de Proteínas Quinases/farmacologia
[Mh] Termos MeSH secundário: Animais
Antineoplásicos/química
Antineoplásicos/farmacologia
Progressão da Doença
Desenho de Drogas
Proteína-Tirosina Quinases de Adesão Focal/genética
Regulação Neoplásica da Expressão Gênica
Seres Humanos
Terapia de Alvo Molecular
Neoplasias/enzimologia
Patentes como Assunto
Inibidores de Proteínas Quinases/química
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Protein Kinase Inhibitors); EC 2.7.10.2 (Focal Adhesion Protein-Tyrosine Kinases)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171207
[St] Status:MEDLINE
[do] DOI:10.1080/13543776.2018.1414183


  10 / 8847 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:29172345
[Au] Autor:Trevor Burke FJ
[Ti] Título:Own label materials: scientific evidence.
[So] Source:Dent Update;44(4):273, 2017 Apr.
[Is] ISSN:0305-5000
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Materiais Dentários/normas
[Mh] Termos MeSH secundário: Indústria Química
Seres Humanos
Patentes como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dental Materials)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180130
[Lr] Data última revisão:
180130
[Sb] Subgrupo de revista:D
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE



página 1 de 885 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde